Alex Azar II, President Donald J. Trump’s nominee to be the administration's second HHS secretary acknowledged that “all drug prices are too high” and said lowering them would be one of his top priorities if confirmed at a Senate Finance Committee hearing today.
The drug pricing issue has become increasing relevant, with prescription prices rising almost 10% in 2016 from the year before. Egregious examples of price increases such as EpiPen’s 500% price increase since 2007, prices of certain dermatology drugs spiking more than 400% since 2009, and oral cancer (Read more...)
Uncategorized